Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1 billion and a commercial presence in more than 50 countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization. He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
David Lubner has more than 20 years of finance and executive leadership experience and served as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, acquired by UCB Pharma in April 2020. Before joining Ra Pharma, David served as Senior Vice President, CFO at Tetraphase Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel antibiotics for the treatment of serious and life-threatening multidrug-resistant (MDR) bacterial infections. He also held CFO roles at PharMetrics, Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition, David serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), Therapeutics Acquisition Corporation (Nasdaq: RACA), and several other private companies and previously served on the Board of Directors of Nightstar Therapeutics until its acquisition by Biogen in June 2019. He is a Certified Public Accountant (CPA) in the Commonwealth of Massachusetts and a member of the American Institute of CPAs. David received his bachelor’s degree in accounting and business management from Northeastern University and a master’s degree in taxation from Bentley University.
V S Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions. He is a qualified Chartered Accountant from India and has nearly 30 years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations. Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Ltd. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement. Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Dr. Olanoff was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Dr. Olanoff served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations. Dr. Olanoff also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than 200 completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. He received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
Dr. Sonia Quaratino has over twenty-five years of experience in research in immunology, clinical development at large pharmaceutical and biotechnology companies, has served on multiple boards, and overseen research programs at leading academic institutions. Most recently, Dr. Quaratino was Chief Medical Officer for Kymab, a biotech based in Cambridge with an innovative pipeline in immuno-oncology and immunology that was acquired by Sanofi in 2021. Dr. Quaratino has been Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics since May of 2020 and a non-executive director for TargoVax ASA since March of 2021. Previously, she held roles as Global Clinical Program Leader in Translational Clinical Oncology at Novartis in Basel and as Senior Medical Director and Immunology Advisor at Merck Serono in Darmstadt. At the University of Southampton, where she was Professor of Immunology, her research group focused on the interface between autoimmunity and cancer. Dr. Quaratino received her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo, and her Ph.D. in Immunology from Imperial College London.
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Concerning Your Privacy